OSE Immunotherapeutics, a clinical-stage biotechnology company based in Nantes, France, has selected CLEC-1 for its oral presentation at the second Virtual Annual Meeting of American Association of Cancer Research (AACR). After conducting research, CLEC-1 has been identified as a fresh myeloid immune checkpoint target, for cancer immunotherapy.
The newly collected data about CLEC-1 comes through a joint research conducted by OSE’s research and development team in collaboration with Dr. Elize Chiffoleau from Center for Research in Transplantation and Immunology.
The data on CLEC-1 indicates that it is a new therapeutic target in immuno-oncology, claims Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics. He has further added that antagonists of the CLEC-1 receptor represent an all-new cancer immunotherapy approach that is in synergy with chemotherapy. CLEC-1's identification adds more value to OSE’s work in the field of myeloid cells and macrophages, asserts Poirier.
For the uninitiated, myeloid cells accumulate in the tumor microenvironment and tend to deregulate the immune activation of T-lymphocytes. CLEC-1 is a C-type lectin receptor that inhibits suppressive actions of myeloid cells and restores the anti-tumor response by T-lymphocytes.
The key findings of the research to be presented at AACR include -
- CLEC-1 is a new “Don’t eat me” signal analogous to the SIRPα-CD47 axis
- CLEC-1 antibodies effectively restore the phagocytosis function of macrophages and dendritic cells
- CLEC-1 recognizes stress and necrosis of tumor cells and acts as a “sensor of death”
- CLEC-1 completely removes tumor cells when combined with cytotoxic immunogenic chemotherapy
- CLEC-1 blocks the cross-priming of T-lymphocytes and lessens adaptative memory immune response.
The AACR Virtual Annual Meeting II is scheduled to be held on June 22-24, 2020.
About OSE Immunotherapeutics
OSE Immunotherapeutics is a biotechnology company headquartered in Nantes, France. It works in the areas of immuno-oncology and auto-immune diseases. Over years, it has created a scientific and technological profile in the fields of neoepitopes and antagonist monoclonal anti-bodies. Its portfolio includes several projects such as Tedopi, BI765063, FR-104 and CoVepiT.